Given that recently published study suggests that 68Ga-PSMA-11 PET/MRI may have benefits over PET/CT regarding detection rate of recurrent prostate cancer at very low PSA-levels (Kranzbuhler et al., 2018). This evidence concerns the gene FOLH1 and prostate cancer.